RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:A pilot study of the immune microenvironment of GI neuroendocrine carcinoma.
A pilot study of the immune microenvironment of GI neuroendocrine carcinoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
胃肠胰高等级神经内分泌癌(GEP-NEC)是一种侵袭性恶性肿瘤,治疗选择有限,在美国的发病率不断上升。由于该癌症罕见且原发肿瘤部位异质,关于GEP-NEC肿瘤发生及其与宿主免疫系统相互作用的数据有限。深入了解GEP-NEC及其肿瘤微环境(TME),有助于开发更有效的靶向疗法,并合理调整针对该病的免疫治疗。
本研究使用NanoString nCounter PanCancer IO 360平台,对21份GEP-NEC患者活检样本中的770个独特基因进行表达谱分析。
结果显示GEP-NEC肿瘤微环境存在若干趋势:年龄小于60岁及总生存期(OS)较长患者的TME中,提示免疫细胞浸润的基因表达更高。非胰腺NEC患者肿瘤的MHC II表达低于胰腺NEC,提示胰腺GEP-NEC亚型可能存在更显著的适应性免疫反应。OS超过6个月的患者,其肿瘤NK细胞基因特征高于生存较差者。
此外,分析发现多个基因在患者年龄、肿瘤部位、治疗反应及OS方面存在差异表达,仍需进一步验证其与临床结局的关系。
Gastroenteropancreatic high-grade (HG) neuroendocrine carcinoma (GEP-NEC) is an aggressive malignancy with limited treatment options and increasing incidence in the United States. Due to the rarity of the cancer and heterogeneity of the primary tumor location, data on GEP-NEC oncogenesis and its interaction with the host immune system are limited.
A greater understanding of GEP-NEC and its tumor microenvironment (TME) would benefit efforts to develop more effective targeted therapies and rationally adapt immunotherapy to this disease. In this study, we profiled the expression of 770 unique genes using 21 biopsy samples from patients with GEP-NEC using the NanoString nCounter PanCancer IO 360 platform.
Our results show several trends evident within the GEP-NEC TME. Greater expression of genes indicative of immune cell infiltration was present within the TME of patients <60 years of age and in patients with greater overall survival (OS). Tumors from patients with non-pancreatic NEC had diminished MHCII expression compared to pancreatic NEC, suggesting more prominent adaptive immune responses in the pancreatic GEP-NEC subtype. Patients with a >6 months OS had tumors with elevated NK cell gene signatures compared to patients with poor survival.
Further, the analysis revealed numerous differentially expressed genes based on patient age, tumor location, response to treatment, and OS, which warrant future validation for assessing the relationship with clinical outcomes in patients.
MEMBER ACCOUNT
登录成功会直接打开下一页。